80.68
Schlusskurs vom Vortag:
$82.46
Offen:
$82.5
24-Stunden-Volumen:
330.28K
Relative Volume:
0.62
Marktkapitalisierung:
$5.36B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-20.69
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
-2.74%
1M Leistung:
+7.57%
6M Leistung:
-0.79%
1J Leistung:
-0.57%
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NUVL
Nuvalent Inc
|
80.68 | 5.96B | 0 | -224.29M | -185.06M | -3.90 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-14 | Hochstufung | UBS | Neutral → Buy |
2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
2024-10-24 | Eingeleitet | UBS | Neutral |
2024-08-29 | Eingeleitet | Barclays | Overweight |
2024-04-17 | Eingeleitet | Jefferies | Buy |
2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-02-28 | Fortgesetzt | Guggenheim | Buy |
2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
2023-09-27 | Eingeleitet | Stifel | Buy |
2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
2023-07-24 | Eingeleitet | Guggenheim | Buy |
2023-01-18 | Eingeleitet | Wedbush | Outperform |
2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
What drives Nuvalent Inc. stock priceGame-changing returns - Autocar Professional
Is Nuvalent Inc. a good long term investmentHigh-impact stock picks - jammulinksnews.com
Nuvalent Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com
What analysts say about Nuvalent Inc. stockUnprecedented profit potential - jammulinksnews.com
Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times
Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks
Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com India
Nuvalent announces initiation of Alkazar phase 3 randomized - MarketScreener
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PR Newswire
How high can Nuvalent Inc. stock price go in 2025Profitable Yet Secure Picks - Newser
Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest
Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World
Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser
How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser
Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World
Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest
Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Nuvalent (NUVL) Gets a Buy from Goldman Sachs - The Globe and Mail
Nuvalent (NASDAQ:NUVL) Upgraded at The Goldman Sachs Group - Defense World
Goldman Sachs initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com India
Goldman Sachs initiates coverage on Nuvalent stock with Buy rating - Investing.com
Nuvalent chief development officer Noci sells $314k in shares - Investing.com
Barclays Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader - insights.citeline.com
Nuvalent (NUVL) Receives Raised Price Target from Baird | NUVL Stock News - GuruFocus
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):